Advertisement

Topics

Keeping An Eye On Regeneron: What's Next To Drive Growth

11:43 EST 8 Nov 2017 | SCRIP

Regeneron is looking to expansion of Eylea to diabetic retinopathy and Dupixent to asthma and other indications to drive mid-term...

      

Related Stories

 

Original Article: Keeping An Eye On Regeneron: What's Next To Drive Growth

NEXT ARTICLE

More From BioPortfolio on "Keeping An Eye On Regeneron: What's Next To Drive Growth"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Diabetes
Diabetes is a lifelong condition that causes a person's blood sugar level to become too high. The two main types of diabetes are: type 1 diabetes type 2 diabetes In the UK, diabetes affects approximately 2.9 million people. There are a...

Allergies
The term allergy is used to describe a response, within the body, to a substance, which is not necessarily harmful in itself, but results in an immune response and a reaction that causes symptoms and disease in a predisposed person, which in turn can cau...